A
Alan Fix
Researcher at PATH
Publications - 15
Citations - 540
Alan Fix is an academic researcher from PATH. The author has contributed to research in topics: Rotavirus vaccine & Rotavirus. The author has an hindex of 9, co-authored 15 publications receiving 341 citations. Previous affiliations of Alan Fix include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial
Michelle J. Groome,Anthonet Koen,Alan Fix,Nicola Page,Nicola Page,Lisa Jose,Shabir A. Madhi,Shabir A. Madhi,Monica M. McNeal,Len Dally,Iksung Cho,Maureen Power,Jorge Flores,Stanley J. Cryz +13 more
TL;DR: The parenteral P2-VP8-P[8] vaccine was well tolerated and immunogenic in infants, providing a novel approach to vaccination against rotavirus disease in South African toddlers and infants.
Journal ArticleDOI
A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants
Prasad S. Kulkarni,Sajjad Desai,Tushar Tewari,Anand Kawade,Nidhi Goyal,Bishan S Garg,Dinesh Kumar,Suman Kanungo,Veena Kamat,Gagandeep Kang,Ashish Bavdekar,Sudhir Babji,Sanjay Juvekar,Byomkesh Manna,Shanta Dutta,Rama Angurana,Deepika Dewan,Abhijeet Dharmadhikari,Jagdish Kamalaji Zade,Rajeev M. Dhere,Alan Fix,Maureen Power,Vidyasagar Uprety,Varsha Parulekar,Iksung Cho,Temsunaro Rongsen Chandola,Vikash K. Kedia,Abhishek V Raut,Jorge Flores,Hanif Shaikh,Lalit Gupta,Rakesh Patil,Mohd. Aslam,Alok Arya,Farhana Afzal Rafiqi,Subodh S Gupta,Chetna Maliye,P. V. Bahulekar,Kiran Bala,Tajali Nazir Shora,Shahid Hussain,Mihir K. Bhattacharya,Ashis K. Mukhopadhyay,Dilipkumar Pal,Jayanta K. Saha,Ranjitha S Shetty,Muralidhar M Kulkarni,Chythra V. Raj +47 more
TL;DR: The Pentavalent reassortant rotavirus vaccine showed excellent tolerability and a good safety profile when tested for efficacy in infants and the intent to treat analyses confirmed all the per protocol analyses.
Journal ArticleDOI
Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial
Firdausi Qadri,Marjahan Akhtar,Taufiqur Rahman Bhuiyan,Mohiul I. Chowdhury,Tasnuva Ahmed,Tanzeem Ahmed Rafique,Arifuzzaman Khan,Sadia Isfat Ara Rahman,Farhana Khanam,Anna Lundgren,Gudrun Wiklund,Joanna Kaim,Madeleine Löfstrand,Nils Carlin,A. Louis Bourgeois,Nicole Maier,Alan Fix,Thomas F. Wierzba,Richard I. Walker,Ann-Mari Svennerholm +19 more
TL;DR: The encouraging safety and immunogenicity of ETVAX and benefit of dmLT adjuvant in young children support its further assessment for protective efficacy in children in enterotoxigenic E coli-endemic areas.
Journal ArticleDOI
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
Ilse De Coster,Isabel Leroux-Roels,Ananda S Bandyopadhyay,Chris Gast,Kanchanamala Withanage,Katie Steenackers,Philippe De Smedt,Annelies Aerssens,Geert Leroux-Roels,M. Steven Oberste,Jennifer L. Konopka-Anstadt,William C. Weldon,Alan Fix,John Konz,Rahnuma Wahid,John F. Modlin,John F. Modlin,Ralf Clemens,Sue Ann Costa Clemens,Novilia S Bachtiar,Pierre Van Damme +20 more
TL;DR: Two novel type 2 oral poliovirus vaccine (OPV2) candidates, designed to be more genetically stable than the licensed Sabin monovalent OPV2, have been developed to respond to ongoing polio outbreaks due to circulating vaccine-derived type 2 polioviruses.
Journal ArticleDOI
Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults
Alan Fix,Clayton Harro,Monica M. McNeal,Len Dally,Jorge Flores,George A. Robertson,John W. Boslego,Stanley J. Cryz +7 more
TL;DR: The P2-VP8 subunit vaccine was well tolerated and evoked promising immune responses, and neutralizing antibodies to homologous and heterologous strains of rotavirus were robust to P[8] strains, moderate toP[4] strains and negligible to P,[6] strains.